System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Thomas Filleron, PhD is an expert in Oncology at Oncopole Claudius Regaud (France). Thomas Filleron has authored 413 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 2 of them ongoing. SLR score: 1,417 (community average: 125). How the SLR is computed.

LeadR Profile

Thomas Filleron, PhD Oncopole Claudius Regaud France
1 417 ScienceLeadR Reputation 1417

Unlock

Register Login
Network Map

Oncology

Subspecialties: Gynecology - Public Health - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2004 - 2026
Source: PubMed

Oncopole Claudius Regaud

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 413

Citations

Citations: 10 127 1st author: 17 Last author: 49 Unique author: 1

Main journals

Cancer Res 35
Ann Oncol 30
J Clin Oncol 24
Radiother Oncol 17
Int J Radiat Oncol Biol Phys 14

Best Journals

Ann Oncol 12
J Clin Oncol 7
Nature 3

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer.
PMID 42777032 — cells, lung, biological science disciplines, pharmaceutical preparations, neoplasms, lung neoplasms, therapeutics, mutation		Sci Adv20260
Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial.
PMID 42585966 — breast neoplasms, docetaxel, neoplasms, drug therapy, breast, anthracyclines, therapeutics, chemotherapy		Breast20260
Treatment patterns and outcomes in advanced and metastatic lung cancer in France: Results from the Epidemiological Strategy and medical Economics (ESME) database lung cancer in France.
PMID 42660015 — cells, lung, neoplasms, carcinoma, non-small-cell lung, economics, medical, lung neoplasms, therapeutics, economics		Lung Cancer20260
The concept of functional cure in advanced/metastatic melanoma treated with combined nivolumab and ipilimumab or nivolumab alone.
PMID 42399508 — melanoma, neoplasms, nivolumab, ipilimumab		Br J Cancer20260
Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France.
PMID 42252502 — research design, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, therapeutics, mutation, prognosis, her2 mutation		Cancer Med20260

Clinical Studies 19

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 6
Phase 2 6
Phase 3 5
Phase 1 1
Phase 4 1

By status:

Completed 13
Recruiting 4
Terminated 1
Unknown 1

By type:

Interventional 15
Observational 4

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 1
multicentric5to9 2
multicentricup10 12

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
PARa aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer
NCT05581121 — radiotherapy, carcinoma, adenosquamous, lymph nodes, lymph node excision, uterine cervical neoplasms, brachytherapy, neoplasms, adenocarcinoma, laparoscopy, human papillomavirus 16, lymph, therapeutics, carcinoma		Phase 3Recruiting2023
Adapted Physical Activity for Children Treated With Cancer and Insulin Sensitivity
NCT05383092 — exercise, insulin resistance, muscles, hospitalization, insulin, neoplasms, metabolic syndrome, child		N/ARecruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS